Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Cutaneous T-cell Lymphoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

TNFRSF8 positive	Cutaneous T-cell Lymphoma	TNFRSF8 positive	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	bexarotene oral Sensitive: A1 - Approval bexarotene oral Sensitive : A1	bexarotene oral Sensitive: A1 - Approval bexarotene oral Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	vorinostat Sensitive: A1 - Approval vorinostat Sensitive : A1	vorinostat Sensitive: A1 - Approval vorinostat Sensitive : A1
IL2RA expression	Cutaneous T-cell Lymphoma	IL2RA expression	Cutaneous T-cell Lymphoma	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	denileukin diftitox-cxdl Sensitive: A1 - Approval denileukin diftitox-cxdl Sensitive : A1	denileukin diftitox-cxdl Sensitive: A1 - Approval denileukin diftitox-cxdl Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B
TNFRSF8 expression	Cutaneous T-cell Lymphoma	TNFRSF8 expression	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	KT-333 Sensitive: B - Late Trials KT-333 Sensitive : B	KT-333 Sensitive: B - Late Trials KT-333 Sensitive : B
PD-L1 underexpression	Cutaneous T-cell Lymphoma	PD-L1 underexpression	Cutaneous T-cell Lymphoma	durvalumab + lenalidomide Sensitive: C3 – Early Trials durvalumab + lenalidomide Sensitive : C3	durvalumab + lenalidomide Sensitive: C3 – Early Trials durvalumab + lenalidomide Sensitive : C3
RPS6 underexpression	Cutaneous T-cell Lymphoma	RPS6 underexpression	Cutaneous T-cell Lymphoma	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
ICOS underexpression	Cutaneous T-cell Lymphoma	ICOS underexpression	Cutaneous T-cell Lymphoma	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
PD-1 overexpression	Cutaneous T-cell Lymphoma	PD-1 overexpression	Cutaneous T-cell Lymphoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CD70 expression	Cutaneous T-cell Lymphoma	CD70 expression	Cutaneous T-cell Lymphoma	ARGX-110 Sensitive: C3 – Early Trials ARGX-110 Sensitive : C3	ARGX-110 Sensitive: C3 – Early Trials ARGX-110 Sensitive : C3
IL10-L	Cutaneous T-cell Lymphoma	IL10-L	Cutaneous T-cell Lymphoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
TNFA-L	Cutaneous T-cell Lymphoma	TNFA-L	Cutaneous T-cell Lymphoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CCL20-L	Cutaneous T-cell Lymphoma	CCL20-L	Cutaneous T-cell Lymphoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
TNFRSF8 positive	Cutaneous T-cell Lymphoma	TNFRSF8 positive	Cutaneous T-cell Lymphoma	gemcitabine + doxorubicin hydrochloride Sensitive: C3 – Early Trials gemcitabine + doxorubicin hydrochloride Sensitive : C3	gemcitabine + doxorubicin hydrochloride Sensitive: C3 – Early Trials gemcitabine + doxorubicin hydrochloride Sensitive : C3
TNFRSF8 expression	Cutaneous T-cell Lymphoma	TNFRSF8 expression	Cutaneous T-cell Lymphoma	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D	TEQ102 Sensitive: D – Preclinical TEQ102 Sensitive : D